Shares of GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) have earned an average recommendation of “Hold” from the nineteen brokerages that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $56.30.
A number of equities analysts have recently commented on the stock. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $67.40 to $55.90 in a research note on Thursday, October 29th. Sanford C. Bernstein reiterated a “buy” rating on shares of GSK in a research note on Sunday, August 2nd. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Berenberg Bank reaffirmed a “buy” rating on shares of GSK in a research note on Tuesday, October 6th. Finally, Citigroup started coverage on shares of GSK in a research note on Friday, July 24th. They set a “neutral” rating for the company.
Check Out Our Latest Research Report on GSK
GSK Price Performance
Shares of NYSE:GSK opened at $50.41 on Friday. The company has a market cap of $101.96 billion, a P/E ratio of 10.66, a PEG ratio of 2.28 and a beta of 0.29. GSK has a 52 week low of $45.81 and a 52 week high of $61.69. The company has a 50-day moving average price of $49.31 and a 200 day moving average price of $52.40. The company has a quick ratio of 0.56, a current ratio of 0.86 and a debt-to-equity ratio of 1.18.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be paid a dividend of $0.4518 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date is Friday, November 13th. This is an increase from GSK’s previous quarterly dividend of $0.4515. GSK’s dividend payout ratio is currently 61.46%.
Institutional Trading of GSK
A number of hedge funds and other institutional investors have recently made changes to their positions in GSK. Mondrian Investment Partners LTD boosted its position in shares of GSK by 1.1% in the 3rd quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock worth $239,210,000 after purchasing an additional 55,116 shares during the last quarter. Equity Investment Corp grew its stake in shares of GSK by 8.9% in the third quarter. Equity Investment Corp now owns 3,560,824 shares of the pharmaceutical company’s stock valued at $171,525,000 after acquiring an additional 291,059 shares in the last quarter. Russell Investments Group Ltd. raised its stake in GSK by 2.1% in the third quarter. Russell Investments Group Ltd. now owns 1,060,376 shares of the pharmaceutical company’s stock valued at $51,078,000 after purchasing an additional 22,275 shares in the last quarter. NewEdge Advisors LLC boosted its stake in GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after buying an additional 852,437 shares in the last quarter. Finally, First Trust Advisors LP grew its position in GSK by 10.5% in the third quarter. First Trust Advisors LP now owns 708,091 shares of the pharmaceutical company’s stock valued at $34,109,000 after acquiring an additional 67,456 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.
GSK Company Profile
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.
Recommended Stories
- Five stocks we like better than GSK
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
